MedTrace Logo

Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma

NCT04231370 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-05-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Sintilimab in combination with lenalidomide in the treatment of Relapsed/Refractory NK/T-cell lymphoma patients who failed pegaspargase-based regimens.

Conditions

  • NK/T Cell Lymphoma Nos

Interventions

DRUG

Sintilimab

Sintilimab, 200mg, iv day1

DRUG

Lenalidomide

25mg/d oral d1-14

Sponsors & Collaborators

  • Beijing Tongren Hospital

    lead OTHER

Principal Investigators

  • Jing-wen Wang, M.D. · Beijing Tongren Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2022-02-28
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04231370 on ClinicalTrials.gov